Healthcare - Press Releases

STRASBOURG, France, MONTREAL, BOSTON, March 20, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing DT-9046, a candidate with game-changingpotentialin multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine.

NES ZIONA,Israel, March 20, 2025 /PRNewswire/ -- EyeYon Medical, a global leader in innovative corneal implant solutions, is proud to announce that Dr. Ofer Daphna, the inventor of EndoArt, will deliver an invited keynote lecture at the prestigious World Cornea Congress (WCC) 2025 in Washington, D.C., this weekend. Dr. Daphna will present a decade of groundbreaking development behind EndoArt and share insights from the successful treatment of 500 patients, with nearly six (6) years of follow-up data.

NES ZIONA,Israel, March 20, 2025 /PRNewswire/ -- EyeYon Medical, a global leader in innovative corneal implant solutions, is proud to announce that Dr. Ofer Daphna, the inventor of EndoArt, will deliver an invited keynote lecture at the prestigious World Cornea Congress (WCC) 2025 in Washington, D.C., this weekend. Dr. Daphna will present a decade of groundbreaking development behind EndoArt and share insights from the successful treatment of 500 patients, with nearly six (6) years of follow-up data.

NES ZIONA,Isral, 20 mars 2025 /PRNewswire/ -- EyeYon Medical, leader mondial des solutions innovantes d'implants cornens, est fier d'annoncer que le Dr Ofer Daphna, l'inventeur d'EndoArt, sera invit donner une confrence lors du prestigieux Congrs mondial de la corne (WCC) 2025 Washington, D.C., ce week-end. Le Dr Daphna prsentera une dcennie de dveloppement rvolutionnaire derrire EndoArt et partagera ses connaissances sur le traitement russi de 500 patients, avec prs de six (6) ans de donnes de suivi.

NES ZIONA,Israel, 20. Mrz 2025 /PRNewswire/ -- EyeYon Medical, ein weltweit fhrender Anbieter innovativer Hornhautimplantatlsungen, ist stolz darauf, bekannt zu geben, dass Dr. Ofer Daphna, der Erfinder von EndoArt, an diesem Wochenende auf dem angesehenen World Cornea Congress (WCC) 2025 in Washington, D.C., einen eingeladenen Hauptvortrag halten wird. Dr. Daphna wird die bahnbrechende Entwicklung von EndoArt in den letzten zehn Jahren vorstellen und die Erkenntnisse aus der erfolgreichen Behandlung von 500 Patienten mit einer Nachbeobachtungszeit von fast sechs (6) Jahren vorstellen.

HOUSTON, March 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro-hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced its CEO, Dr. Tom Vo, will present at the EDPMA Solutions Summit 2025. This event will take place fromMarch 30 to April 2 at The Broadmoor in Colorado Springs, CO.

Company announcementNo. 03/2025

Company announcementNo. 03/2025

OXFORD, England, March 20, 2025 /PRNewswire/ --Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1,to treat patients with oesophageal cancer.

With the pilot line environment, non-invasive devices enabling early cancer detection and remote heart disease monitoring can advance from research and development to market faster than before, benefiting patients more quickly. Established by VTT with an investment of EUR 3.4 million, the facility is unique in Europe and is focused in particular on medical devices based on photonics technology.

The multiple myeloma market is expected to grow in the upcoming years, owing to a rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newer therapies, mainly CAR-T cell therapies and bispecific antibodies, a rich emerging pipeline, and an expected increase in investment in R&D activities.

Hepatic Artery Infusion therapy delivers treatment directly tometastatic tumors in the liver, while minimizing the potential for systemic side effects

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With a high unmet need in these areas and limited competition, EMPAVELI's market is poised for steady growth.

New AI-Powered Support Assistant Helps Blood Cancer Patients Find Answers and Resources Faster

SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.

PARIS und SAN FRANCISCO, 19. Mrz 2025 /PRNewswire/ -- Moon Surgical, ein franzsisch-amerikanischer Pionier auf dem Gebiet der chirurgischen Innovation, gab heute die Zulassung von ScoPilot durch die US-amerikanische Food and Drug Administration (FDA) bekannt. Ermglicht durch NVIDIA Holoscan, eine Echtzeit-Sensorplattform, die fr die Entwicklung und den Einsatz von auf knstlicher Intelligenz basierenden Anwendungen im Operationssaal konzipiert ist und lokal unter dem Maestro-System von Moon Surgical ausgefhrt wird. ScoPilot ist die erste KI-Anwendung, die intraoperativ auf jeder handelsblichen chirurgischen Roboterplattform mit Holoscan luft.

SAN FRANCISCO andSUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the FRUSICA-2 Phase 2/3 clinical trial evaluating sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint of progression free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR).

BOSTON, March 19, 2025 /PRNewswire/ -- The surge in online supplement sales has led to a troubling rise in counterfeit products infiltrating e-commerce platforms, deceiving buyers with misleading packaging and false advertising. ProDentim, Bioventra's brand, a well-established name in health and wellness, is issuing a consumer warning regarding unauthorized resellers distributing imitation versions of its product. The company has identified multiple fraudulent listings across online marketplaces, raising concerns about product authenticity and customer safety.

NEW YORK, March 19, 2025 /PRNewswire/ -- The rise of counterfeit supplements has become a growing concern across the health and wellness industry, with unauthorized sellers misrepresenting legitimate brands and deceiving consumers with unverified products.AquaSculpt's manufacturer Bioventrahas launched an aggressive crackdown against unauthorized resellers, ensuring that customers receive only the authentic, high-quality formula through official channels.

CORTA Y CORRE: La Sociedad Europea de Ciruga Plstica, Reconstructiva y Esttica (ESPRAS) destaca el preocupante xodo de la Generacin Z hacia la prctica privada

LONDRES, 19 mars 2025 /PRNewswire/ --Une nouvelle tude a mis en vidence l'impact de la gnration Z sur la main-d'uvre chirurgicale, qui est l'origine d'un changement inquitant puisqu'elle dlaisse la chirurgie reconstructive au profit d'opportunits lucratives dans le secteur de l'esthtique.

STOCKHOLM, March 19, 2025 /PRNewswire/ -- Sobi (STO: SOBI),today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant (emapalumab) for the potential treatment of interferon-gamma (IFN)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress by Prof. Giamarellos-Bourboulis, from the Hellenic Institute for the Study of Sepsis. The study underscores Sobi's commitment to advancing medicine through targeted therapies for severe and complex conditions such as sepsis, a leading cause of mortality globally.

VADUZ,Liechtenstein, March 19, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStopfor the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the RefluxStopprocedure is now being performed at the Hospital Vithas 9 de Octubre, inValencia, Spain.

LONDON, March 19, 2025 /PRNewswire/ --A new study has highlighted the impact of Gen Z on the surgical workforce, who are driving a worrying change as they move away from reconstructive surgery in favour of lucrative opportunities in the aesthetics sector.

Green Oak Ranch